Literature DB >> 20601954

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Gorica Nikoloski1, Saskia M C Langemeijer, Roland P Kuiper, Ruth Knops, Marion Massop, Evelyn R L T M Tönnissen, Adrian van der Heijden, Theresia N Scheele, Peter Vandenberghe, Theo de Witte, Bert A van der Reijden, Joop H Jansen.   

Abstract

In myelodysplastic syndromes (MDS), deletions of chromosome 7 or 7q are common and correlate with a poor prognosis. The relevant genes on chromosome 7 are unknown. We report here that EZH2, located at 7q36.1, is frequently targeted in MDS. Analysis of EZH2 deletions, missense and frameshift mutations strongly suggests that EZH2 is a tumor suppressor. As EZH2 functions as a histone methyltransferase, abnormal histone modification may contribute to epigenetic deregulation in MDS.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20601954     DOI： 10.1038/ng.620

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  13 in total

1.  Nomenclature for the description of human sequence variations.

Authors:  J T den Dunnen; S E Antonarakis
Journal:  Hum Genet       Date:  2001-07       Impact factor: 4.132

2.  Histone methyltransferase activity of a Drosophila Polycomb group repressor complex.

Authors:  Jürg Müller; Craig M Hart; Nicole J Francis; Marcus L Vargas; Aditya Sengupta; Brigitte Wild; Ellen L Miller; Michael B O'Connor; Robert E Kingston; Jeffrey A Simon
Journal:  Cell       Date:  2002-10-18       Impact factor: 41.582

3.  Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites.

Authors:  Birgit Czermin; Raffaella Melfi; Donna McCabe; Volker Seitz; Axel Imhof; Vincenzo Pirrotta
Journal:  Cell       Date:  2002-10-18       Impact factor: 41.582

4.  Role of histone H3 lysine 27 methylation in Polycomb-group silencing.

Authors:  Ru Cao; Liangjun Wang; Hengbin Wang; Li Xia; Hediye Erdjument-Bromage; Paul Tempst; Richard S Jones; Yi Zhang
Journal:  Science       Date:  2002-09-26       Impact factor: 47.728

5.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein.

Authors:  Andrei Kuzmichev; Kenichi Nishioka; Hediye Erdjument-Bromage; Paul Tempst; Danny Reinberg
Journal:  Genes Dev       Date:  2002-11-15       Impact factor: 11.361

6.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Authors:  Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl
Journal:  Blood       Date:  2007-08-28       Impact factor: 22.113

7.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

8.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

9.  Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling.

Authors:  Anne-Marie Martinez; Bernd Schuettengruber; Samy Sakr; Ana Janic; Cayetano Gonzalez; Giacomo Cavalli
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Authors:  Ryan D Morin; Nathalie A Johnson; Tesa M Severson; Andrew J Mungall; Jianghong An; Rodrigo Goya; Jessica E Paul; Merrill Boyle; Bruce W Woolcock; Florian Kuchenbauer; Damian Yap; R Keith Humphries; Obi L Griffith; Sohrab Shah; Henry Zhu; Michelle Kimbara; Pavel Shashkin; Jean F Charlot; Marianna Tcherpakov; Richard Corbett; Angela Tam; Richard Varhol; Duane Smailus; Michelle Moksa; Yongjun Zhao; Allen Delaney; Hong Qian; Inanc Birol; Jacqueline Schein; Richard Moore; Robert Holt; Doug E Horsman; Joseph M Connors; Steven Jones; Samuel Aparicio; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330
View more
  316 in total

Review 1.  Functional Crosstalk Between Lysine Methyltransferases on Histone Substrates: The Case of G9A/GLP and Polycomb Repressive Complex 2.

Authors:  Chiara Mozzetta; Julien Pontis; Slimane Ait-Si-Ali
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

Review 2.  Pathogenesis and consequences of uniparental disomy in cancer.

Authors:  Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Clin Cancer Res       Date:  2011-04-25       Impact factor: 12.531

3.  Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome.

Authors:  Shohei Kikuchi; Masayoshi Kobune; Satoshi Iyama; Tsutomu Sato; Kazuyuki Murase; Yutaka Kawano; Kohichi Takada; Kaoru Ono; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Rishu Takimoto; Junji Kato
Journal:  Int J Hematol       Date:  2012-03-11       Impact factor: 2.490

Review 4.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 5.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

6.  A complex Polycomb issue: the two faces of EZH2 in cancer.

Authors:  Hanno Hock
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

Review 7.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

8.  High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.

Authors:  K C Kawabata; Y Hayashi; D Inoue; H Meguro; H Sakurai; T Fukuyama; Y Tanaka; S Asada; T Fukushima; R Nagase; R Takeda; Y Harada; J Kitaura; S Goyama; H Harada; H Aburatani; T Kitamura
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

9.  Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.

Authors:  Marinus R Heideman; Roel H Wilting; Eva Yanover; Arno Velds; Johann de Jong; Ron M Kerkhoven; Heinz Jacobs; Lodewyk F Wessels; Jan-Hermen Dannenberg
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

Review 10.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.